GlassScriptPhysician profile
Margaret Pan
NPI 1598345407
$3,791.01
in general payments reported to CMS, 2019-2025
31 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $601 · 2023: $600 · 2024: $977 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $334.10 | 2022-2025 | |
| Abbvie INC. | $286.93 | 2025 | |
| Janssen Pharmaceuticals, INC | $273.06 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $230.28 | 2025 | Entyvio |
| Astrazeneca Pharmaceuticals LP | $227.31 | 2022-2024 | Andexxa, Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $225.57 | 2022 | |
| Amgen INC. | $201.72 | 2023-2025 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.29 | 2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $189.02 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $167.12 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $151.85 | 2022-2024 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $130.30 | 2025 | Livdelzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.70 | 2022-2024 | Jardiance |
| Aimmune Therapeutics, INC. | $124.56 | 2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $109.46 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $104.66 | 2023-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $103.02 | 2023-2025 | Eliquis |
| Novo Nordisk INC | $88.22 | 2022-2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $77.58 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $77.51 | 2025 | Dupixent |
| Celltrion USA INC. | $75.45 | 2025 | Vegzelma |
| Philips North America LLC | $63.77 | 2022-2023 | |
| Ardelyx, INC. | $39.83 | 2025 | Ibsrela |
| Kiniksa Pharmaceuticals, LTD. | $35.79 | 2023 | Arcalyst |
| Lilly USA, LLC | $29.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.18 | 2024 | |
| Edwards Lifesciences Corporation | $22.56 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kestra Medical Technology Services, INC. | $22.49 | 2024 | Assure Wcd |
| Cvrx, INC. | $19.97 | 2023 | Barostim Neo System |
| Braintree Laboratories, INC. | $17.81 | 2025 | Sutab, Suflave |
| Arbor Pharmaceuticals, INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.